201 related articles for article (PubMed ID: 31765938)
1. Role of cancer immunology in chronic myelogenous leukemia.
Ureshino H; Shindo T; Kimura S
Leuk Res; 2020 Jan; 88():106273. PubMed ID: 31765938
[TBL] [Abstract][Full Text] [Related]
2. Treatment-free remission and immunity in chronic myeloid leukemia.
Ureshino H
Int J Hematol; 2021 May; 113(5):642-647. PubMed ID: 33651270
[TBL] [Abstract][Full Text] [Related]
3. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG
Front Immunol; 2018; 9():3152. PubMed ID: 30705677
[TBL] [Abstract][Full Text] [Related]
4. Allelic polymorphisms of
Shindo T; Ureshino H; Kojima H; Tanaka H; Kimura S
Immunol Med; 2021 Jun; 44(2):61-68. PubMed ID: 32715973
[TBL] [Abstract][Full Text] [Related]
5. [Chronic myeloid leukemia and NK cell immunity].
Ureshino H; Shindo T; Tanaka H; Kimura S
Rinsho Ketsueki; 2017; 58(4):381-388. PubMed ID: 28484170
[TBL] [Abstract][Full Text] [Related]
6. Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape.
Hsieh YC; Kirschner K; Copland M
Leukemia; 2021 May; 35(5):1229-1242. PubMed ID: 33833387
[TBL] [Abstract][Full Text] [Related]
7. Effect of Age on NK Cell Compartment in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors.
Rodrigues-Santos P; López-Sejas N; Almeida JS; Ruzičková L; Couceiro P; Alves V; Campos C; Alonso C; Tarazona R; Freitas-Tavares P; Solana R; Santos-Rosa M
Front Immunol; 2018; 9():2587. PubMed ID: 30487792
[TBL] [Abstract][Full Text] [Related]
8. Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.
Hughes A; Yong ASM
Front Immunol; 2017; 8():469. PubMed ID: 28484463
[TBL] [Abstract][Full Text] [Related]
9. NKT-Like (CD3+CD56+) Cells in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors.
Almeida JS; Couceiro P; López-Sejas N; Alves V; Růžičková L; Tarazona R; Solana R; Freitas-Tavares P; Santos-Rosa M; Rodrigues-Santos P
Front Immunol; 2019; 10():2493. PubMed ID: 31695700
[TBL] [Abstract][Full Text] [Related]
10. Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha.
Pawelec G; Da Silva P; Max H; Kalbacher H; Schmidt H; Bruserud O; Zügel U; Baier W; Rehbein A; Pohla H
Leuk Lymphoma; 1995 Aug; 18(5-6):471-8. PubMed ID: 8528055
[TBL] [Abstract][Full Text] [Related]
11. [Immunological evaluation for CML and its possibility for an immunotherapy].
Fujii S
Nihon Rinsho Meneki Gakkai Kaishi; 2009 Aug; 32(4):231-41. PubMed ID: 19721343
[TBL] [Abstract][Full Text] [Related]
12. Macrophages protect mycoplasma-infected chronic myeloid leukemia cells from natural killer cell killing.
Choo QWW; Koean RAG; Chang SC; Chng WJ; Chan MC; Wang W; Er JZ; Ding JL
Immunol Cell Biol; 2020 Feb; 98(2):138-151. PubMed ID: 31837284
[TBL] [Abstract][Full Text] [Related]
13. Dynamics and potential impact of the immune response to chronic myelogenous leukemia.
Kim PS; Lee PP; Levy D
PLoS Comput Biol; 2008 Jun; 4(6):e1000095. PubMed ID: 18566683
[TBL] [Abstract][Full Text] [Related]
14. Development, Function, and Clinical Significance of Plasmacytoid Dendritic Cells in Chronic Myeloid Leukemia.
Inselmann S; Wang Y; Saussele S; Fritz L; Schütz C; Huber M; Liebler S; Ernst T; Cai D; Botschek S; Brendel C; Calogero RA; Pavlinic D; Benes V; Liu ET; Neubauer A; Hochhaus A; Burchert A
Cancer Res; 2018 Nov; 78(21):6223-6234. PubMed ID: 30166420
[TBL] [Abstract][Full Text] [Related]
15. γδ T Cells Number, CD200, and Flt3 Expression Is Associated with Higher Progression Free Survival in Patients with Chronic Myeloid Leukemia.
Molina-Aguilar R; Montiel-Cervantes LA; Anguiano-Peñaloza SV; Lezama R; Vela-Ojeda J; Reyes-Maldonado E
Arch Med Res; 2020 Apr; 51(3):194-203. PubMed ID: 32113783
[TBL] [Abstract][Full Text] [Related]
16. Natural killer and lymphokine-activated killer cell functions in chronic myeloid leukemia.
Rajaram N; Tatake RJ; Advani SH; Naik SL; Gangal SG
Cancer Immunol Immunother; 1990; 31(1):44-8. PubMed ID: 2306755
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
18. Sustained treatment-free remission in chronic myeloid leukaemia is associated with an increased frequency of innate CD8(+) T-cells.
Cayssials E; Jacomet F; Piccirilli N; Lefèvre L; Roy L; Guilhot F; Chomel JC; Leleu X; Gombert JM; Herbelin A; Barbarin A
Br J Haematol; 2019 Jul; 186(1):54-59. PubMed ID: 30864168
[TBL] [Abstract][Full Text] [Related]
19. [Tyrosine kinase inhibitor therapy discontinuation for chronic myelogenous leukemia to achieve clinical cure: current status and future perspectives].
Kumagai T
Rinsho Ketsueki; 2018; 59(10):2094-2103. PubMed ID: 30305514
[TBL] [Abstract][Full Text] [Related]
20. CML Hematopoietic Stem Cells Expressing IL1RAP Can Be Targeted by Chimeric Antigen Receptor-Engineered T Cells.
Warda W; Larosa F; Neto Da Rocha M; Trad R; Deconinck E; Fajloun Z; Faure C; Caillot D; Moldovan M; Valmary-Degano S; Biichle S; Daguindau E; Garnache-Ottou F; Tabruyn S; Adotevi O; Deschamps M; Ferrand C
Cancer Res; 2019 Feb; 79(3):663-675. PubMed ID: 30514753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
